Free Trial

Precipio Q2 2024 Earnings Report

Precipio logo
$5.27 +0.12 (+2.33%)
As of 03:48 PM Eastern

Precipio EPS Results

Actual EPS
-$0.83
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Precipio Revenue Results

Actual Revenue
$4.44 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Precipio Announcement Details

Quarter
Q2 2024
Time
N/A

Conference Call Resources

Remove Ads

Precipio Earnings Headlines

Trump’s Final Plan
Presidential insider exposes shocking plot to reshape U.S. economy: The 2025 Trump Reset -- Inside Trump’s secret plan to trigger the greatest transfer of wealth since FDR and LBJ – trillions of dollars could be redistributed.
Precipio Reports Positive Q4 Financial Results
See More Precipio Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Precipio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Precipio and other key companies, straight to your email.

About Precipio

Precipio (NASDAQ:PRPO), a healthcare solutions company, provides diagnostic products, reagents, and services in the United States. It provides diagnostic blood cancer testing services. The company offers IV-Cell, a proprietary cell culture media that enables simultaneous culturing of four hematopoietic cell lineages; and HemeScreen, a suite of robust genetic diagnostic panels. It offers biomarker testing and clinical project services to bio-pharma customers. The company is based in New Haven, Connecticut.

View Precipio Profile

More Earnings Resources from MarketBeat